Table 2 Patients remitting from chronic migraine (CM) to episodic migraine (EM) and from medication overuse (MO) to no medication overuse (no-MO) across weeks 4, 8 and 12 following fremanezumab treatment
Week 4 | Week 8 | Week 12 | |
|---|---|---|---|
CM remission to EM | 22/36 (61.1%) | 26/36 (72.2%) | 27/36 (75%) |
Sustained remission across weeks 4, 8, 12 | - | 22/22 (100%) | 21/22 (95.5%) |
MO remission to no-MO | 19/31 (61.2%) | 20/31 (64.5%) | 21/31 (67.7%) |
Sustained remission across weeks 4, 8, 12 | - | 18/19 (94.7%) | 17/19 (94.4%) |